Health Care & Life Sciences » Pharmaceuticals | Neos Therapeutics Inc.

Neos Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2015
2016
2017
2018
Sales/Revenue
3,792.00
9,154.00
25,018.00
49,988
Cost of Goods Sold (COGS) incl. D&A
5,547.00
11,437.00
12,391.00
26,928
Gross Income
1,755.00
2,283.00
12,627.00
23,060
SG&A Expense
24,823.00
74,123.00
69,643.00
66,556
EBIT
26,578.00
76,406.00
57,016.00
43,496
Unusual Expense
1,313.00
1,205.00
509.00
224
Non Operating Income/Expense
831.00
1,215.00
44.00
1,019
Interest Expense
3,721.00
6,937.00
10,085.00
8,974
Pretax Income
30,781.00
83,333.00
66,247.00
51,675
Consolidated Net Income
30,781.00
83,333.00
66,247.00
51,675
Net Income
30,781.00
83,333.00
66,247.00
51,675
Net Income After Extraordinaries
30,781.00
83,333.00
66,247.00
51,675
Net Income Available to Common
33,171.00
83,333.00
66,247.00
51,675
EPS (Basic)
4.38
5.19
2.68
1.60
Basic Shares Outstanding
7,581.90
16,052.40
24,751.10
32,288.60
EPS (Diluted)
4.38
5.19
2.68
1.60
Diluted Shares Outstanding
7,581.90
16,052.40
24,751.10
32,288.60
EBITDA
23,336.00
73,146.00
53,993.00
40,009
Non-Operating Interest Income
-
-
301.00
-
Preferred Dividends
2,390.00
-
-
-

About Neos Therapeutics

View Profile
Address
2940 North Highway 360
Grand Prairie Texas 75050
United States
Employees -
Website http://www.neostx.com
Updated 07/08/2019
Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.